Trials / Completed
CompletedNCT00243191
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Sarcoma Alliance for Research through Collaboration · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | imatinib mesylate | 400 mg orally twice a day for 10 - 14 days |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2005-10-21
- Last updated
- 2012-03-29
- Results posted
- 2012-03-29
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00243191. Inclusion in this directory is not an endorsement.